S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Ligand Pharmaceuticals Stock Forecast, Price & News

+1.36 (+1.52%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
135,181 shs
Average Volume
157,169 shs
Market Capitalization
$1.53 billion
P/E Ratio
Dividend Yield
Price Target

Ligand Pharmaceuticals Stock Forecast (MarketRank)

Analyst Rating
3.00 Rating Score
99.6% Upside
$180.83 Price Target
Short Interest
5.38% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.62mentions of Ligand Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$206.90 K Bought Last Quarter
Proj. Earnings Growth
From $0.55 to $1.57 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.58 out of 5 stars

Medical Sector

61st out of 1,428 stocks

Pharmaceutical Preparations Industry

18th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Ligand Pharmaceuticals logo

About Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

LGND Stock News Headlines

Ligand Pharma Tops Q1 EPS by 10c
Ligand Pharmaceuticals Q1 2022 Earnings Preview
Ligand Pharmaceuticals: Moving Parts Keep Moving
A New SPAC Deal Is a Fresh Idea for the M&A Industry
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
$57.14 million
Pretax Margin


Sales & Book Value

Annual Sales
$277.13 million
Cash Flow
$8.85 per share
Book Value
$49.14 per share


Free Float
Market Cap
$1.53 billion

Ligand Pharmaceuticals Frequently Asked Questions

Should I buy or sell Ligand Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ligand Pharmaceuticals stock.
View analyst ratings for Ligand Pharmaceuticals
or view top-rated stocks.

What is Ligand Pharmaceuticals' stock price forecast for 2022?

5 Wall Street research analysts have issued 12-month price targets for Ligand Pharmaceuticals' shares. Their LGND stock forecasts range from $130.00 to $310.00. On average, they predict Ligand Pharmaceuticals' share price to reach $180.83 in the next year. This suggests a possible upside of 99.6% from the stock's current price.
View analysts' price targets for Ligand Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Ligand Pharmaceuticals' stock performed in 2022?

Ligand Pharmaceuticals' stock was trading at $154.46 at the start of the year. Since then, LGND shares have decreased by 41.4% and is now trading at $90.58.
View the best growth stocks for 2022 here

When is Ligand Pharmaceuticals' next earnings date?

Ligand Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Ligand Pharmaceuticals

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its earnings results on Wednesday, May, 4th. The biotechnology company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.19 by $0.04. The biotechnology company had revenue of $45.70 million for the quarter, compared to the consensus estimate of $34.21 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 8.29% and a net margin of 9.00%. The company's revenue for the quarter was down 17.2% compared to the same quarter last year. During the same period last year, the firm earned $1.03 earnings per share.
View Ligand Pharmaceuticals' earnings history

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of $1.70-$2.20 for the period, compared to the consensus estimate of $3.22. The company issued revenue guidance of $147.00 million-$172.00 million, compared to the consensus revenue estimate of $162.39 million.

Who are Ligand Pharmaceuticals' key executives?

Ligand Pharmaceuticals' management team includes the following people:
  • Mr. John L. Higgins, CEO & Exec. Director (Age 52, Pay $1.23M)
  • Mr. Matthew W. Foehr, Pres & COO (Age 49, Pay $909k)
  • Mr. Matthew E. Korenberg, Exec. VP of Fin. & CFO (Age 47, Pay $753.25k)
  • Mr. Charles S. Berkman J.D., Sr. VP, Gen. Counsel & Sec. (Age 53, Pay $665.83k)
  • Simon Latimer, Head of Investor Relations
  • Mr. Todd Pettingill, Director of Corp. Devel.
  • Ms. Audrey Warfield-Graham, Sr. VP of HR
  • Dr. Keith Marschke, Sr. VP of Biology & Scientific Affairs
  • Dr. Vincent D. Antle, Sr. VP of Technical Operations & QA - Capitsol (Age 53)
  • Mr. Patrick Lucy, Sr. VP & CBO Protein Expression Bus.

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?

1 employees have rated Ligand Pharmaceuticals CEO John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among Ligand Pharmaceuticals' employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $90.58.

How much money does Ligand Pharmaceuticals make?

Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.53 billion and generates $277.13 million in revenue each year. The biotechnology company earns $57.14 million in net income (profit) each year or $1.379990 on an earnings per share basis.

How many employees does Ligand Pharmaceuticals have?

Ligand Pharmaceuticals employs 154 workers across the globe.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for Ligand Pharmaceuticals is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826.

This page (NASDAQ:LGND) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.